Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

Sai Life Sciences

PR94141

 

HYDERABAD, India, Jan. 19, 2022 /PRNewswire=KYODO JBN/--

 

    Sai Life Sciences, a leading global Contract Research, Development &

Manufacturing Organization [

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=sauri-gudlavalleti-joins-sai-life-sciences-as-coo]

(CRO-CDMO), today announced the appointment of Sauri Gudlavalleti as its Chief

Operating Officer. Sauri will report to the CEO & Managing Director, Krishna

Kanumuri and drive the company's growth as a new generation, science-driven

organization.

 

    Making the announcement, Krishna Kanumuri said, "I am really excited to

welcome Sauri on board Sai Life Sciences! He brings with him a strong

data-driven, systems approach combined with an innovation mindset and customer

focus. I am confident that this approach will help us build Sai Life Sciences

for greater scale, with high-quality science, speed and operating efficiency as

the key pivots of our growth."

 

    Sauri joins Sai Life Sciences from Dr. Reddy's Laboratories where he was

heading Global R&D and Portfolio Management for small molecule API &

Formulations, encompassing portfolio & strategy, development, technology

transfer, CRO/ CDMO partnerships, IP, regulatory affairs and clinical affairs.

Over his 7-year tenure there, he spearheaded a multifold increase in the R&D

pipeline, significantly globalized the R&D efforts with an impetus on

fast-growing emerging markets and brought about a pioneering transformation in

R&D through data and analytics. More recently, Sauri led the development,

approval and launch of the company's covid portfolio, partnering with global

large pharma innovators, in record time.

 

    Before Dr. Reddy's, Sauri was at McKinsey & Co. for six years where he

successfully delivered on several client engagements with focus on operational

transformation spanning product development, service delivery and manufacturing

operations. Previously, he spent 9 years in the US, working on advanced

technologies at MIT, GE and Qualcomm. He holds 9 US patents and has published

in multiple peer-reviewed journals and conferences. Sauri is a B.Tech from IIT

Madras, an MS from MIT and an MBA from IIM Ahmedabad.

 

    Responding to his appointment, Sauri Gudlavalleti, COO said, "I am

delighted to join Sai Life Sciences at such an exciting time in its journey. In

all my interactions with the various leaders of the company, I have sensed much

excitement and a strong commitment to building a high-quality scientific

company that brings science to life for its customers. This resonates with my

own personal vision of transforming Pharma R&D with innovative technologies,

data and analytics."

 

    Over the past couple of years, the company has undergone an intense phase

of transformation as part of its Sai Nxt initiative [

https://www.sailife.com/sai-nxt/?utm_source=pr&utm_medium=web&utm_campaign=sauri-gudlavalleti-joins-sai-life-sciences-as-coo].

During this period, it has expanded into new geographies, executed investments

of over US$100M in its capacity and operations, grew its workforce across

locations, consolidated discovery operations from Pune to Hyderabad, and more.

As a result of these efforts, the progress in its trajectory across both its

Discovery and CMC businesses shows a tremendous uptick in the recent months.

 

    About Sai Life Sciences

 

    Sai Life Sciences is a full-service CRO-CDMO [

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=sauri-gudlavalleti-joins-sai-life-sciences-as-coo]

that works with innovator pharma and biotech companies globally, to accelerate

the discovery, development and commercialisation of complex small molecules.

The company has over 2200 employees across its facilities in India, UK and USA.

Sai Life Sciences is privately held and backed by global investors, TPG Capital

and HBM Healthcare Investments. https://www.sailife.com/

    

    Image: https://mma.prnewswire.com/media/1729548/Sauri_Gudlavalleti.jpg

    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

 

    Source - Sai Life Sciences

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中